25 February 2003
Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats--role of anti-intestinal motility mediated by D2 receptors.
Tohru Miyazawa, Masahiro Matsumoto, Shinichi Kato, Koji TakeuchiMed Sci Monit 2003; 9(2): BR71-77 :: ID: 4766
Abstract
BACKGROUND: Although it is known that dopamine prevents various gastrointestinal lesions, the underlying mechanism remains unclear. In the present study, we examined the protective effect of dopamine on indomethacin-induced small intestinal lesions, in relation to intestinal hypermotility. MATERIAL/METHODS: Male SD rats received indomethacin (10 mg/kg) subcutaneously (s.c.), and the small intestine was examined for lesions 24 hr later. Dopamine (1-10 mg/kg) or atropine (3 mg/kg) was administered s.c. twice, 30 min before and 8 hr after indomethacin, while sulpiride (3 mg/kg) and domperidone (3 mg/kg), the dopamine D2 receptor antagonists, or yohimbine (10 mg/kg), the alpha2-adrenoceptor antagonist, were administered s.c. twice, 30 min before each dosing of dopamine. Intestinal motility was measured using a balloon under urethane anesthesia. RESULTS: Indomethacin caused severe lesions in the small intestine, mainly both the jejunum and ileum. The intestinal ulcerogenic response to indomethacin was dose-dependently prevented by dopamine as well as atropine. The protective effect of dopamine was almost totally antagonized by domperidone and sulpiride but not by yohimbine. On the other hand, indomethacin markedly enhanced intestinal motility, and the hypermotility response was also prevented by dopamine as well as atropine. Both sulpiride and domperidone, but not yohimbine, also antagonized the inhibitory effect of dopamine on the indomethacin-induced intestinal hypermotility. CONCLUSIONS: These results suggest that dopamine protects the small intestine against indomethacin-induced damage, probably by inhibiting the intestinal hypermotility mediated by dopamine D2 receptors.
Keywords: Domperidone - pharmacology, Intestinal Diseases - chemically induced, Intestinal Diseases - physiopathology, Intestinal Diseases - prevention & control, Intestine, Small - pathology
733 8
Editorial
01 May 2023 : Editorial
Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor TherapyDOI: 10.12659/MSM.940911
Med Sci Monit 2023; 29:e940911
In Press
31 May 2023 : Review article
Prevalence, Diagnosis, and Management of Eclampsia and the Need for Improved Maternal Care: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.939919
30 May 2023 : Clinical Research
A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodi...Med Sci Monit In Press; DOI: 10.12659/MSM.940409
30 May 2023 : Review article
A Review of the Role of the Zebrafish (Danio reiro) in Preclinical and Clinical Models of Biomarker Identif...Med Sci Monit In Press; DOI: 10.12659/MSM.940550
30 May 2023 : Database Analysis
The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952